β2-AR have been shown to sustain HCC cells proliferation, survival and chemoresistance [144]; hence, the use of β-AR blockers or sympathetic denervation represents a promising therapeutic strategy [137,145,146]. The gene discussed is ADRB2; the disease is hepatocellular carcinoma.